Embecta Corp, established in 2022 and headquartered in New Jersey, is a leading provider of innovative diabetes care solutions. The company aims to improve the lives of people with diabetes by offering a range of products, including insulin delivery devices and advanced technology for glucose monitoring.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| EMBC 5.00% 2030-02-15 USDEmbecta Corp | United States | 2030-02-15 | 5.000 | 6.36 |
| EMBC 5.00% 2030-02-15 USDEmbecta Corp | United States | 2030-02-15 | 5.000 | 6.39 |
| EMBC 6.75% 2030-02-15 USDEmbecta Corp | United States | 2030-02-15 | 6.750 | 7.06 |
| EMBC 6.75% 2030-02-15 USDEmbecta Corp | United States | 2030-02-15 | 6.750 | 7.06 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Embecta Corp began issuing bonds shortly after its formation, with its first issuance occurring in late 2022 to support its expansion initiatives. A significant issuance came in early 2023, when the company raised $500 million to enhance its manufacturing capabilities and research and development efforts. Currently, Embecta's bonds yield about 4.5%, which is competitive within the healthcare sector, reflecting investor confidence in its growth strategy. Notably, the bonds feature a call option that allows Embecta to redeem them early if it achieves certain financial milestones.